New cell therapy targets returning brain tumors
NCT ID NCT06254326
First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 27 times
Summary
This early-phase trial tests a new treatment for a type of brain cancer called oligodendroglioma that has come back or is growing. The treatment uses the patient's own immune cells (dendritic cells, T cells, and stem cells) combined with targeted drugs. The main goals are to see if the treatment is safe and possible to deliver. The study plans to enroll up to 12 adults whose tumors have returned after standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT OLIGODENDROGLIOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Florida Health Shands Hospital
Gainesville, Florida, 32610, United States
Conditions
Explore the condition pages connected to this study.